K11020—Medicine - Atherosclerosis Research Unit

Contact:

Mentor: Jere P. Segrest, M.D. Professor Mailing address: BDB 630 1530 3RD AVENUE S BIRMINGHAM AL 35294-0012 Telephone: (205) 934-4070 Fax: (205) 975-8079 E-mail :This email address is being protected from spambots. You need JavaScript enabled to view it.


A Postdoctoral Fellowship is available for a Physical Chemist/Biochemist/Structural Biologist to study detailed molecular structures of apolipoprotein (apo) A-I on high density lipoprotein (HDL). Focus is on pathways for in vivo assembly of cholesteryl ester (CE)-rich (spheroidal) HDL, including the structure/dynamics of phospholipid (PL)-poor (preß) and PL-rich (discoidal) HDL. The driving hypothesis is that apoA-I is a uniquely elastic lipid-clamp capable of absorbing PL and CE in increments of a few molecules at a time. Because of a recent demonstration by our lab of the power of MD simulations to provide supramolecular images of HDL, experimental approaches combined with MD simulations uniquely position us to gain fundamental new insights into the structure/function of HDL subspecies. Candidates should have obtained a Ph.D. degree within the past 3 years with a strong background in physicochemistry, biochemistry and structural biology. A highly motivated and independent scientist able to work within an interdisciplinary team is preferred. E-mail research summary, CV, and 3 references to: Jere P. Segrest: This email address is being protected from spambots. You need JavaScript enabled to view it.   or http://www.aru.uab.edu  

UAB News

  • As kids prepare to head back to school, required immunizations are typically on the to-do list, but getting potentially lifesaving vaccines should not end when adulthood begins, says one University of Alabama at Birmingham infectious diseases expert.

  • effrey R. Curtis, M.D., from the University of Alabama at Birmingham, and colleagues utilized 1998 to 2011 data from the U.S. Veterans Health Administration to identify RA patients initiating rituximab, abatacept, or anti-tumor necrosis factor (anti-TNF) therapy. The authors sought to assess the comparative risk of hospitalized infection associated with anti-TNF and non-anti-TNF biologic agents.

UAB Research News

  • New drugs to slow or even prevent Parkinson’s could be in human studies as early as 2015.Written by Matt Windsor An enzyme closely associated with genetic forms of Parkinson’s disease appears to play a larger role in its progression than previously thought, say investigators at the University of Alabama at Birmingham. The new research offers encouraging evidence that drugs to block this enzyme, known as leucine-rich repeat kinase 2 or LRRK2, could slow — or even...

  • UAB School of Nursing's federally funded study shows both the patient and caregiver benefit from early palliative care.The earlier a specific phone-based, palliative care support program can be introduced to caregivers, the better they will be able to cope with the caregiving experience, according to research conducted by University of Alabama at Birmingham School of Nursing investigators. The patient outcomes from the study, known as ENABLE III, were presented June 3 at the American Society of...